S 3440
A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
This bill aims to ensure states have fair access to essential COVID-19 supplies like monoclonal antibodies. It prohibits the federal government from prioritizing federal contracts over state contracts when purchasing these supplies and restricts the President’s ability to limit states’ access to therapies. Furthermore, it allows states to use COVID-19 relief funds to purchase supplies they were previously unable to obtain due to federal prioritization. Finally, it prevents the FDA from rationing or restricting the availability of approved medications during the pandemic.
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.